Synthetic Biologics Inc.
SYN
AMX
Sector: Healthcare
Industry: Biotechnology
0.23
USD
0.00
(-1.74%)
Optionable: No Market Cap: 36 M 90-day average vol: 862,344
Previous close: 0.23 Open: 0.2375 Bid: 0.22 Ask: 0.22
52 week range
0.18 0.57
Last updated: Wednesday 6th July 2022
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 0.54 |
PE Ratio (TTM) | -2.10 |
Book Value per Share ($) | 0.43 |
5 Year PE Range-3 |
Returns
7 Day Return | 13.00% | |
1 Month Return | 5.61% | |
3 Month Return | -13.11% | |
1 Year Return | -58.37% | |
3 Year Return | -61.05% | |
5 Year Return | -98.83% | |
YTD Return | -16.97% |
Risk
Financial Health
Technicals
RSI (14 Day) | 60.18 |
14 Day SMA ($) | 0.20 |
14 Day EMA ($) | 0.21 |
Money Flow Index | 46.45 |
Average True Range | 0.02 |
50 Day SMA ($) | 0.22 |
200 Day SMA ($) | 0.30 |
ADX | 32.05 |
MACD | 0.00 |
Growth
Free Cash Flow QoQ Growth | 123.10% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 100.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference
Yahoo Finance 2/9/2022
Synthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug status
Seeking Alpha 2/8/2022
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
Yahoo Finance 2/8/2022
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
Yahoo Finance 1/26/2022
Synthetic Biologics to acquire VCN Biosciences for over $4M in upfront cash
Seeking Alpha 12/14/2021
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Yahoo Finance 12/14/2021
Synthetic Biologics, Inc.'s (SYN) CEO Steven Shallcross on Q3 2021 Results - Earnings Call Transcript
Seeking Alpha 11/3/2021
Synthetic Biologics EPS beats by $0.01
Seeking Alpha 11/3/2021
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
Yahoo Finance 11/3/2021
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021
Yahoo Finance 10/26/2021
Synthetic Biologics initiates early-stage trial for SYN-020 intestinal alkaline phosphatase
Seeking Alpha 10/21/2021
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
Yahoo Finance 10/21/2021
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Yahoo Finance 10/6/2021
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Yahoo Finance 9/21/2021
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
Yahoo Finance 9/10/2021
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2021 Results - Earnings Call Transcript
Seeking Alpha 8/5/2021
Synthetic Biologics EPS in-line
Seeking Alpha 8/5/2021
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
Yahoo Finance 8/5/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
| NA |
|---|
| NA |
|---|
Financials
SYN Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of sales | -63000 | -43000 | -20000 | -72000 | -157000 | -245000 | -272000 | -240000 | -201000 |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling Gen & administrative expense | 5 M | 6 M | 6 M | 8 M | 10 M | 7 M | 6 M | 5 M | 5 M |
| Research & development expense | 12 M | 7 M | 14 M | 33 M | 29 M | 19 M | 12 M | 11 M | 5 M |
| Operating income | -17 M | -12 M | -21 M | -41 M | -39 M | -26 M | -18 M | -16 M | -10 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -18000 | -12000 | 715000 | -4 M | 11 M | 11 M | 4 M | 0 | 0 |
| Pre-tax Income (EBT) | -17 M | -12 M | -20 M | -45 M | -28 M | -15 M | -13 M | -15 M | -10 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -17 M | -12 M | -20 M | -45 M | -28 M | -15 M | -13 M | -15 M | -10 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -17 M | -12 M | -20 M | -44 M | -27 M | -15 M | -13 M | -15 M | -10 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | 7 M | 12 M | 773000 | 2 M |
| Net income available for common | -17 M | -12 M | -20 M | -45 M | -28 M | -22 M | -25 M | -16 M | -12 M |
| Depreciation | 63000 | 43000 | 20000 | 72000 | 157000 | 245000 | 272000 | 240000 | 201000 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -17 M | -12 M | -20 M | -41 M | -39 M | -26 M | -17 M | -15 M | -10 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -17.15 | -9.45 | -11.2 | -18.9 | -10.15 | -6.23 | -4.06 | -0.98 | -0.66 |
| Diluted EPS total | -17.15 | -9.45 | -11.2 | -18.9 | -10.15 | -6.23 | -4.06 | -0.98 | -0.66 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!